DE602004025834D1 - Die behandlung von tumoren - Google Patents

Die behandlung von tumoren

Info

Publication number
DE602004025834D1
DE602004025834D1 DE602004025834T DE602004025834T DE602004025834D1 DE 602004025834 D1 DE602004025834 D1 DE 602004025834D1 DE 602004025834 T DE602004025834 T DE 602004025834T DE 602004025834 T DE602004025834 T DE 602004025834T DE 602004025834 D1 DE602004025834 D1 DE 602004025834D1
Authority
DE
Germany
Prior art keywords
tumors
microtubule
spores
agents
found
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004025834T
Other languages
English (en)
Inventor
Long Dang
Chetan Bettegowda
Kenneth W Kinzler
Bert Vogelstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of DE602004025834D1 publication Critical patent/DE602004025834D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/842—Clostridium
DE602004025834T 2003-10-22 2004-10-21 Die behandlung von tumoren Active DE602004025834D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51292303P 2003-10-22 2003-10-22
PCT/US2004/034625 WO2005039492A2 (en) 2003-10-22 2004-10-21 Improved combination bacteriolytic therapy for the treatment of tumors

Publications (1)

Publication Number Publication Date
DE602004025834D1 true DE602004025834D1 (de) 2010-04-15

Family

ID=34520062

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004025834T Active DE602004025834D1 (de) 2003-10-22 2004-10-21 Die behandlung von tumoren

Country Status (5)

Country Link
US (3) US8007782B2 (de)
EP (1) EP1675465B1 (de)
AT (1) ATE459364T1 (de)
DE (1) DE602004025834D1 (de)
WO (1) WO2005039492A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009017908A1 (de) * 2009-04-17 2010-10-21 Kist-Europe Forschungsgesellschaft Mbh Vektor für den Transport von mikrobiologischen Organismen zu Krankheitsherden
PT2707030T (pt) 2011-05-09 2020-05-22 Mayo Found Medical Education & Res Tratamentos de cancro
CA2917407C (en) 2012-10-01 2023-03-14 Mayo Foundation For Medical Education And Research Complexes containing albumin-containing nanoparticles and antibodies to treat cancer
JP6125041B2 (ja) 2013-01-02 2017-05-10 デコイ バイオシステムズ インコーポレイテッドＤｅｃｏｙ Ｂｉｏｓｙｓｔｅｍｓ， Ｉｎｃ． 細菌を用いた癌治療用組成物およびその製造のための菌の使用
EP2968440B1 (de) 2013-03-15 2019-06-05 Zymeworks Inc. Zytotoxische und antimitotische verbindungen und verfahren zur verwendung davon
WO2014160967A2 (en) * 2013-03-29 2014-10-02 Biomed Valley Discoveries, Inc. C. novyi for the treatment of solid tumors in non-human animals
JP6756609B2 (ja) 2013-03-29 2020-09-16 バイオメッド バレー ディスカバリーズ，インコーポレイティド ヒトにおける固形腫瘍の処置のためのＣ．ｎｏｖｙｉ
ES2916722T3 (es) 2013-12-27 2022-07-05 Zymeworks Inc Sistemas de enlace que contienen sulfonamida para conjugados de fármacos
CA2935064C (en) 2013-12-27 2023-06-27 Zymeworks Inc. Var2csa-drug conjugates
CN107041139A (zh) 2014-05-28 2017-08-11 艾更斯司股份有限公司 海兔脯氨酸‑海兔异亮氨酸肽的衍生物
US10213513B2 (en) 2014-06-16 2019-02-26 Mayo Foundation For Medical Education And Research Treating myelomas
CA2960899C (en) 2014-09-17 2021-08-17 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
WO2016123313A1 (en) 2015-01-29 2016-08-04 Oxyrase, Inc. Methods for inhibiting tumor growth
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
EP3399861A4 (de) 2016-01-07 2019-08-07 Mayo Foundation for Medical Education and Research Verfahren zur behandlung von krebs mit interferon
EP3413874A4 (de) 2016-02-12 2020-01-22 Mayo Foundation for Medical Education and Research Behandlungen für blutkrebs
US11305020B2 (en) 2016-03-21 2022-04-19 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
AU2017238118A1 (en) 2016-03-21 2018-10-11 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
RU2019109209A (ru) 2016-09-01 2020-10-05 Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч Способ и композиции для направленного на мишень воздействия при лечении т-клеточных видов рака
KR20220151022A (ko) 2016-09-01 2022-11-11 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 암 치료용 담체－ｐｄ－ｌ１ 결합제 조성물
US11590098B2 (en) 2016-09-06 2023-02-28 Mayo Foundation For Medical Education And Research Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
US11311631B2 (en) * 2016-09-06 2022-04-26 Mayo Foundation For Medical Education And Research Paclitaxel-albumin-binding agent compositions and methods for using and making the same
KR20230011473A (ko) 2016-09-06 2023-01-20 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 Ｐｄ－ｌ１ 발현 암의 치료 방법
GB201801977D0 (en) * 2018-02-07 2018-03-28 Knauf Insulation Doo Skofja Loka Recycling
CN111001014B (zh) * 2019-12-12 2022-04-22 四川大学华西医院 一种基于固定细菌做载体的抗肿瘤药物及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688517A (en) * 1993-01-29 1997-11-18 Napro Biotherapeutics, Inc. Method for assessing sensitivity of tumor cells to cephalomannine and 10-deacetyltaxol
US5554638A (en) * 1993-05-24 1996-09-10 Duke University Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders
EP0877622B1 (de) * 1996-02-02 2004-08-18 Zentaris GmbH Methode zur inaktivierung von proteinen der ras-unterfamilie und verbindungen dafuer
EP1446012B1 (de) * 2001-11-21 2013-07-17 The Johns Hopkins University Bakteriolytische kombinationstherapie für die behandlung von tumoren
ITMI20012497A1 (it) * 2001-11-28 2003-05-28 Agriplast S N C Perfezionamento nei tubi per l'irrigazione a goccia
WO2005039491A2 (en) 2003-10-22 2005-05-06 The John Hopkins University Certain improved combination bacteriolytic therapy for the treatment of tumors

Also Published As

Publication number Publication date
US20110311500A1 (en) 2011-12-22
WO2005039492A3 (en) 2005-06-30
US8613917B2 (en) 2013-12-24
EP1675465A4 (de) 2008-07-30
US9572843B2 (en) 2017-02-21
US20140328813A1 (en) 2014-11-06
US8007782B2 (en) 2011-08-30
ATE459364T1 (de) 2010-03-15
US20070148135A1 (en) 2007-06-28
EP1675465B1 (de) 2010-03-03
WO2005039492A9 (en) 2005-06-02
EP1675465A2 (de) 2006-07-05
WO2005039492A2 (en) 2005-05-06

Similar Documents

Publication Publication Date Title
DE602004025834D1 (de) Die behandlung von tumoren
Achkar et al. Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway
Utsumi et al. Effect of indirect nonequilibrium atmospheric pressure plasma on anti-proliferative activity against chronic chemo-resistant ovarian cancer cells in vitro and in vivo
Dick et al. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy
Chou et al. Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies
De Ridder et al. Hypoxic tumor cell radiosensitization through nitric oxide
Prochazka et al. Mitochondrial targeting overcomes ABCA1-dependent resistance of lung carcinoma to α-tocopheryl succinate
NO20050793L (no) Anvendelse av urease for inhibering av kreftcellevekst
AR025885A1 (es) Derivados del acido indolil-3-glioxilico con valiosas propiedades terapeuticas
He et al. Potent inhibition of gastric cancer cells by a natural compound via inhibiting TrxR1 activity and activating ROS-mediated p38 MAPK pathway
Roomi et al. Inhibition of pulmonary metastasis of melanoma B16FO cells in C57BL/6 mice by a nutrient mixture consisting of ascorbic acid, lysine, proline, arginine, and green tea extract
De Ridder et al. Hypoxic tumor cell radiosensitization: role of the iNOS/NO pathway
Vazana-Barad et al. Mechanism of the antitumoral activity of deferasirox, an iron chelation agent, on mantle cell lymphoma
ATE269700T1 (de) Verwendung von docetaxel für die behandlung von hepatozelluläre krebs
WO2005039491A3 (en) Certain improved combination bacteriolytic therapy for the treatment of tumors
Douple The use of platinum chemotherapy to potentiate radiotherapy
Menendez et al. Ozone therapy in cancer treatment: State of the art
Friedmann et al. Synergistic effects of valproic acid and mitomycin C in adenocarcinoma cell lines and fresh tumor cells of patients with colon cancer
Masunaga Modification of tirapazamine-induced cytotoxicity in combination with mild hyperthermia and/or nicotinamide: reference to effect on quiescent tumour cells
Yang et al. Improved radiosensitizing effect of the combination of etanidazole and paclitaxel for hepatocellular carcinoma in vivo
Mun et al. Peroxiredoxin 3 has important roles on arsenic trioxide induced apoptosis in human acute promyelocytic leukemia cell line via hyperoxidation of mitochondrial specific reactive oxygen species
Masunaga et al. Combined effects of tirapazamine and mild hyperthermia on anti-angiogenic agent (TNP-470) treated tumors—reference to the effect on intratumor quiescent cells
Watanabe et al. Antivascular effects of TZT‐1027 (Soblidotin) on murine Colon26 adenocarcinoma
Tai et al. Relationship between intracellular glutathione level and the mode of cell death induced by pingyangmycin
Jiang et al. Oncogenic MALT1 promotes cell survival and mediates ibrutinib resistance and ibrutinib-venetoclax resistance in mantle cell lymphoma

Legal Events

Date Code Title Description
8364 No opposition during term of opposition